![]() May play a positive role in bone health by working in concert with other ![]() Thus, the role of manganese in bone health is still being researched ( 4, 5). However, other studies suggest that supplements containing only calcium and vitamin D have similar effects. In addition, a one-year study in women with weak bones found that taking a supplement with these nutrients, as well as vitamin D, magnesium and boron may improve bone mass ( 3). Research suggests that taking manganese with calcium, zinc and copper may help reduce spinal bone loss in older women ( 2). Studies have shown that about 50% of postmenopausal women and 25% of men aged 50 or older will suffer from an osteoporosis-related bone break ( 1). This is particularly important in older adults. When combined with the nutrients calcium, zinc and copper, manganese supports bone mineral density. “The results of the current meta‐analysis study might support the use of chromium supplementationįor the improvement of glycemic control indices in T2DM patients,” they concluded.Manganese is essential for bone health, including bone development and maintenance. “Furthermore, long term intervention contributed to greater reduction of all mentioned indices.” “Present systematic review and meta-analysis of all available published randomized trials up to 2020 found a significant reduction in all glycemic control indices such as fasting plasma glucose, insulin, HbA1c and HOMA-IR levels after chromium supplementation,” they wrote. Other nutrients that have been associated with a lower risk of type 2 diabetes include vitamins A, C, D and E, beta-carotene, calcium, magnesium, potassium and zinc. The authors observed that chromium plays a role in carbohydrate and lipid metabolism and may enhance insulin sensitivity. ![]() Homeostatic model assessment for insulin resistance (HOMA-IR) also decreased significantly among participants who received chromium. Of the 14 trials that reported insulin levels, levels declined by an average of 1.7784 µIU/mL among subjects who received chromium compared to the placebo, with trials that lasted 12 weeks or longer associated with a decrease of 3.47 µIU/mL.įor the 22 trials that reported HbA1c, supplementation with chromium was associated with an average decrease of 0.71%, which improved to a significant 1.70% reduction when trials of 12 weeks duration or more were examined. ![]() Trials of at least 12 weeks duration were associated with a far greater average decrease of 58.74 mg/dL in association with chromium. Eleven of the trials evaluated a chromium dosage within a 400 to 600 mcg range.Īnalysis of 22 trials that reported fasting plasma glucose levels concluded that chromium supplementation was associated with an average reduction of 19.0 milligrams per deciliter (mg/dL) in comparison with the placebo. Doses used in the studies ranged between 50 micrograms (mcg) and 1,000 mcg per day consumed from four to 25 weeks. A systematic review and meta-analysis published on Jin Pharmacological Research found reductions in fasting plasma glucose, insulin, hemoglobin A1c (HbA1c, a marker of long term glucose control) and insulin resistance in men and women with type 2 diabetes who supplemented with the mineral chromium.įor their analysis, Omid Asbaghi of Lorestan University of Medical Sciences and colleagues selected 23 randomized, controlled trials that evaluated the effects of supplementing with chromium on various glycemic control indexes. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |